Alexion Pharmaceuticals, Inc.
DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF PROTEIN-LOSING ENTEROPATHY IN PATIENTS

Abstract:

Provided are methods for clinical treatment of a protein-losing enteropathy, such as lymphangiectasia, using an anti-C5 antibody, or antigen binding fragment thereof, in patients (e.g., pediatric patients).